Literature DB >> 6827684

Chemoimmune prophylaxis of superficial bladder cancer.

H D Adolphs, H P Bastian.   

Abstract

Chemoimmune prophylaxis with intravenous cyclophosphamide and intravesical as well as systemic bacillus Calmette-Guerin treatment was begun after complete tumor resection in 90 patients with superficial urothelial bladder cancer. Compared to a historical patient control group treated by tumor resection alone a distinct decrease in the recurrence rate was noted in the immune treated group, which was most marked during the first 12 months postoperatively. The side effects of this treatment were tolerable. Our results are discussed with regard to the reported findings in the literature. Possible immune biological mechanisms of the tumor protection achieved by cyclophosphamide and bacillus Calmette-Guerin are suggested.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6827684     DOI: 10.1016/s0022-5347(17)51902-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Long-term BCG immune therapy of superficial bladder tumours.

Authors:  L Somogyi; A Szántó; L Polyák; F Baranyay; M Drinóczy
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

2.  Histopathology of BCG and thiotepa treated bladders.

Authors:  P Guinan; M Shaw; V Ray
Journal:  Urol Res       Date:  1986

Review 3.  Invasive bladder cancer--possible future treatment considerations.

Authors:  R A Gardiner
Journal:  Urol Res       Date:  1986

4.  Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma.

Authors:  Bjoern G Volkmer; Evelyn M Seidl-Schlick; Dietmar Bach; Imre Romics; Klaus Kleinschmidt
Journal:  Clin Rheumatol       Date:  2004-12-01       Impact factor: 2.980

5.  The efficacy of intravesical BCG in the treatment of patients with high risk superficial bladder cancer.

Authors:  L Samodai; L Kiss; Z Kolozsy; L Mohácsi
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

6.  Chemoimmune prophylaxis of superficial bladder tumors: results after treatment of 130 patients in 4 years.

Authors:  H D Adolphs; H P Bastian
Journal:  Urol Res       Date:  1983

7.  Cytomorphological and histological studies on the urothelium during and after chemoimmune prophylaxis.

Authors:  H D Adolphs; H W Schwabe; B Helpap; C Volz
Journal:  Urol Res       Date:  1984

Review 8.  Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.

Authors:  Dongkui Song; Thomas Powles; Lei Shi; Lirong Zhang; Molly A Ingersoll; Yong-Jie Lu
Journal:  J Pathol       Date:  2019-06-24       Impact factor: 7.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.